DEFA14A: Aura Biosciences Updates Proxy Statement, Amends Executive and Director Compensation Disclosures
Proxy Statement Supplement
Aura Biosciences amends its proxy statement for the 2024 annual meeting to update disclosures related to executive and director compensation, including changes to named executive officers and corrections to option award calculations.
Summary
- Aura Biosciences has issued a supplement to its definitive proxy statement filed on April 25, 2024, for the annual stockholder meeting on June 20, 2024.
- The supplement amends the sections on Non-Employee Director Compensation, Executive Compensation, and Principal Stockholders.
- The amendments update disclosures for named executive officers to include J. Jill Hopkins, M.D., and remove Cadmus C. Rich, M.D.
- Corrections were made to the calculation of option awards in the Non-Employee Director Compensation and Executive Compensation sections to comply with FASB Accounting Standards Codification Topic 718.
- The supplement does not reflect events after the initial proxy statement filing date and should be read in conjunction with the original proxy statement and subsequent SEC filings.
Sentiment
Score: 7
Explanation: The document is a standard corporate disclosure, providing necessary updates and corrections. The sentiment is neutral to slightly positive as it reflects transparency and adherence to regulatory requirements.
Positives
- The company is providing updated and corrected information to its shareholders regarding executive and director compensation.
- The compensation program is designed to align executive interests with long-term company performance through equity grants.
- The company maintains a 401(k) plan for employees, including executives, to encourage tax-deferred retirement savings.
Future Outlook
The document does not contain specific forward-looking statements beyond the details of the compensation plans and equity awards.
Industry Context
This type of disclosure is standard for publicly traded companies to provide transparency regarding executive and director compensation, allowing investors to assess whether pay is aligned with performance and company goals.
Comparison to Industry Standards
- The document mentions using independent third-party benchmark analytics to inform the mix of compensation, suggesting an awareness of industry standards.
- The company retained Pay Governance to provide market information and analysis relating to executive compensation, indicating a commitment to competitive compensation practices.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Named Executive Officer | Cadmus C. Rich, M.D. | J. Jill Hopkins, M.D. | N/A | Change in executive role |
Stakeholder Impact
- Shareholders receive updated information on executive and director compensation, allowing them to make informed voting decisions.
- Executives and directors are impacted by the updated compensation disclosures and any corrections to option award calculations.
Next Steps
- Stockholders will vote on the proposals outlined in the proxy statement at the annual meeting on June 20, 2024.
Key Dates
| Date | Description |
|---|---|
| January 2015 | Aura Biosciences entered into an employment agreement with Elisabet de los Pinos, Ph.D. |
| October 2017 | Amendment to the employment agreement with Elisabet de los Pinos, Ph.D. |
| August 2018 | Aura Biosciences entered into an employment offer letter with Julie Feder. |
| November 10, 2021 | Schedule 13D filed with the SEC by Medicxi. |
| October 16, 2023 | Effective date of employment offer letter with J. Jill Hopkins, M.D. |
| December 31, 2023 | Data for equity compensation plan information. |
| March 31, 2024 | Date for principal stockholders information. |
| June 14, 2024 | Date of the proxy statement supplement. |
| June 20, 2024 | Date of the annual meeting of stockholders. |
Keywords
proxy statement, executive compensation, director compensation, stock options, named executive officers, Aura Biosciences, stockholders, equity awards
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.